Key regions: United Kingdom, Germany, France, South Korea, Italy
The COVID-19 Vaccines market in Seychelles has been developing at a steady pace in recent months.
Customer preferences: As the COVID-19 pandemic continues to ravage the world, the demand for vaccines has skyrocketed. Seychelles, like many other countries, has been aggressively pursuing vaccination programs to protect its citizens from the virus. The government has been working closely with international organizations to secure vaccine supplies and has been offering free vaccinations to all its residents.
Trends in the market: The Seychelles vaccine market has been dominated by the AstraZeneca and Sinopharm vaccines. While the AstraZeneca vaccine was initially the primary vaccine used in the country, the government has since shifted its focus to the Sinopharm vaccine due to concerns over blood clotting associated with the AstraZeneca vaccine. The Sinopharm vaccine has been shown to be highly effective against the virus, and has been well received by the Seychellois population.
Local special circumstances: One of the unique challenges facing the Seychelles vaccine market is the country's small population size. With just over 98,000 residents, the government has had to work hard to secure enough vaccines to cover the entire population. Despite this challenge, the government has been successful in securing a steady supply of vaccines, and has been able to vaccinate a significant portion of the population.
Underlying macroeconomic factors: The Seychelles economy has been hit hard by the COVID-19 pandemic, with the tourism industry, a key source of revenue, severely impacted. The government has been working to diversify the economy and reduce its reliance on tourism, and the successful vaccination program is a key part of this effort. By vaccinating the population, the government hopes to attract tourists back to the country and jumpstart the economy.In conclusion, the Seychelles vaccine market has been growing steadily in recent months, driven by the government's aggressive vaccination program. The Sinopharm vaccine has emerged as the primary vaccine in the country, and has been well received by the population. The small population size and the country's reliance on tourism are unique challenges facing the market, but the government's successful vaccination program is a step in the right direction towards economic recovery.
Data coverage:
Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.Modeling approach / Market size:
Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.Forecasts:
In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.Additional notes:
Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.
Mon - Fri, 9am - 6pm (EST)
Mon - Fri, 9am - 5pm (SGT)
Mon - Fri, 10:00am - 6:00pm (JST)
Mon - Fri, 9:30am - 5pm (GMT)
Mon - Fri, 9am - 6pm (EST)
